KUALA LUMPUR: Ekuiti Nasional Bhd has announced its investment in Ain Medicare Sdn Bhd, a leading Bumiputera home-grown manufacturer of serile parenteral pharmaceutical products, via its RM1bil Tranche VI fund.
Ekuiti's purchase of a strategic minority shareholding in the company aligns with its mandate to scale Bumiputera enterprises operating in strategic sectors that contribute to Malaysia’s long-term economic resilience.
According to Ekuinas CEO Aliff Omar Mohamad Omar, Malaysia’s pharmaceutical industry is projected to grow at approximately 6.4% annually to reach over RM15bil by 2030, reflecting rising healthcare demand, demographic shifts and strengthening domestic manufacturing capabilities.
"With the country’s focus and advances in the pharmaceutical industry, it is increasingly recognised as a strategic sector that contributes to economic resilience, supply security and higher-value industrial development.
"Institutional capital has an important role in supporting the growth of scalable local players within priority industries. The sector’s long-term fundamentals, underpinned by regulatory strengthening, export expansion and innovation in specialised products, present sustainable growth opportunities while contributing meaningfully to Malaysia’s broader economic aspirations," he said in a statement.
Ekuinas non-independent non-executive director and Permodalan Nasional Bhd president and group chief executive Datuk Rick Ramli added that the investment eflects a continued commitment to strengthening Bumiputera participation in strategic sectors, aligned with Ekuinas’ objective of building leading, scalable Bumiputera enterprises.
"Ain Medicare’s journey exemplifies the ‘Bumiputera Relay Race’ in action, having been supported by VentureTECH from 2017 to 2025 to strengthen its operational capabilities and scale its manufacturing capacity, before progressing to its next phase with Ekuinas."
Ain Medicare currently operates seven manufacturing facilities located in Kota Bharu and Kulim.
The company holds certifications from local and international bodies such as the National Pharmaceutical Regulatory Agency (NPRA), Medical Device Authority (MDA) and International Organization for Standardization (ISO), reflecting strong regulatory standards and quality assurance.
